A Phase 2 Study of 90Y-Ibritumomab Tiuxetan (90Y-Zevalin®) in Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preliminary Report of the Argentinean Cooperative Group

MLA

Jorge Milone, et al. “A Phase 2 Study of 90Y-Ibritumomab Tiuxetan (90Y-Zevalin®) in Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preliminary Report of the Argentinean Cooperative Group.” Blood, vol. 108, Nov. 2006, p. 4688. EBSCOhost, https://doi.org/10.1182/blood.v108.11.4688.4688.

APA

Jorge Milone, Dardo Riveros, Maria Cecilia Foncuberta, Pedro Negri, Juan Dupont, Leandro Riera, Javier Bordone, Maria Ardaiz, Fernando Bezares, Gustavo Milone, & Roberto Cacchione. (2006). A Phase 2 Study of 90Y-Ibritumomab Tiuxetan (90Y-Zevalin®) in Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preliminary Report of the Argentinean Cooperative Group. Blood, 108, 4688. https://doi.org/10.1182/blood.v108.11.4688.4688

Chicago

Jorge Milone, Dardo Riveros, Maria Cecilia Foncuberta, Pedro Negri, Juan Dupont, Leandro Riera, Javier Bordone, et al. 2006. “A Phase 2 Study of 90Y-Ibritumomab Tiuxetan (90Y-Zevalin®) in Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preliminary Report of the Argentinean Cooperative Group.” Blood 108 (November): 4688. doi:10.1182/blood.v108.11.4688.4688.